Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway Inhibition.

ABSTRACT: Gut microbiome (GM) and its either pro-tumorigenic or anti-tumorigenic role is intriguing and constitutes an evolving landscape in translational oncology. It has been suggested that these microorganisms may be involved in carcinogenesis, cancer treatment response and resistance, as well as predisposition to adverse effects. In melanoma patients, one of the most immunogenic cancers, immune checkpoint inhibitors (ICI) and MAPK-targeted therapy-BRAF/MEK inhibitors-have revolutionized prognosis, and the study of the microbiome as a modulating factor is thus appealing. Although BRAF/MEK inhibitors constitute one of the main backbones of treatment in melanoma, little is known about their impact on GM and how this might correlate with immune re-induction. On the contrary, ICI and their relationsh

SUBMITTER: Guardamagna M 

PROVIDER: S-EPMC9569448 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature